Chipscreen(SH:688321) Zheng Quan Zhi Xing·2025-08-14 16:15Core Viewpoint - The report provides a verification of the usage of funds raised by Shenzhen Micron Biotech Co., Ltd. through the issuance of convertible bonds, confirming that the funds have been used in accordance with regulatory guidelines and accurately reflect the company's financial activities as of March 31, 2025 [1][2][3]. Fundraising and Storage - The company raised a total of RMB 500 million by issuing 5 million convertible bonds at a face value of RMB 100 each, with all funds received by July 11, 2022 [2]. - As of March 31, 2025, the total amount stored in designated accounts was RMB 484,537,300.00 [2]. Fund Usage - The report details the usage of the raised funds, with a total of RMB 356,400,958.33 utilized by March 31, 2025 [5]. - The company has made adjustments to the investment projects funded by the raised capital, specifically reallocating funds to meet market demands for a new drug, Seglitazone [3][4]. Changes in Fund Allocation - The company approved a proposal to change the use of part of the funds originally allocated for the production of CS12192 to instead support the production of Seglitazone [3]. - The total amount of funds that were reallocated was RMB 20,592,700.00 [5]. Cash Management of Idle Funds - The company has been authorized to use up to RMB 300 million of temporarily idle funds for cash management, ensuring that this does not affect the ongoing investment plans [4]. - The cash management strategy includes investing in safe, liquid, and guaranteed return products, with a maximum investment period of 12 months [4]. Remaining and Surplus Funds - As of March 31, 2025, there were no surplus funds remaining from the previous fundraising activities [5]. Project Benefits - The report includes an assessment of the benefits realized from the investment projects funded by the raised capital, although some projects are still in progress and have not yet reached their expected operational status [5].